GLOBAL NON OPIOID PAIN TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Global non opioid pain treatment market is estimated to be valued at USD 78.89 billion in 2024 and is expected to reach USD 140.56 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.6% from 2024 to 2031.

Rising prevalence of chronic pain disorders and increasing focus toward developing safer alternatives to opioid analgesics are driving the global non opioid pain treatment market growth. Factors such as growing geriatric population who are more prone to arthritis and other joint disorders, high incidence of cancer and associated pain, and favorable regulatory environment providing a push to research and development of novel therapies are expected to boost demand for non opioid medications. However, factors such as the availability of generic substitutes once patents of major brands expire can hamper the revenue growth of established players.

Market Dynamics:

Global non opioid pain treatment market growth is driven by factors such as growing awareness about risks of long term opioid usage, repetitive stress injuries and rising other work related musculoskeletal disorders, and increasing strategic collaborations between pain drug developers and medical device companies. However, high development cost of novel drug delivery systems and perceived lower efficacy as compared to opioids can hamper the market growth. Growing focus on development of advanced drug formulations, combination therapies, and neurostimulation devices present lucrative opportunities for major players in this industry.

Key Features of the Study:

• This report provides an in-depth analysis of the global non opioid pain treatment market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global non opioid pain treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• The key companies covered as a part of this study include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Fresenius Kabi AG, GSK, Vertex Pharmaceuticals Incorporated, Pacira BioSciences, Collegium Pharmaceuticals, Cara Therapeutics, Akelos, Fidia Farmaceutici S.p.A., Sanofi, Eli Lilly and Company, Merck & Co, and Acorda Therapeutics.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global non opioid pain treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global non opioid pain treatment market.

Detailed Segmentation:

• Drug Type:
  • Non-Steroidal Anti-Inflammatory Drugs
  • Steriods
  • Analgesics 
  • Corticosteroids
  • Others
• Indication:
  • Musco Skeletal Disorders
  • Central Nervous System Disorders
  • Traumatic Pain
  • Chronic Pain
  • Others
• Distribution Channel:
  • Online Pharmacies
  • Retail Pharmacies
  • Hospital Pharmacies
• Region: 
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Reddy’s Laboratories Ltd. 
  • Sun Pharmaceutical Industries Ltd.  
  • Cipla Inc. 
  • Fresenius Kabi AG 
  • GSK
  • Vertex Pharmaceuticals Incorporated
  • Pacira BioSciences
  • Collegium Pharmaceuticals
  • Cara Therapeutics
  • Akelos
  • Fidia Farmaceutici S.p.A. 
  • Sanofi 
  • Eli Lilly and Company
  • Merck & Co
  • Acorda Therapeutics